Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.

International immunopharmacology 20120101

Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.

International immunopharmacology 20120101

Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.

Evidence-based complementary and alternative medicine : eCAM 20120101

PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.

Pulmonary pharmacology & therapeutics 20110801

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

International immunopharmacology 20110601

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

The Cochrane database of systematic reviews 20110511

GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.

The Journal of pharmacology and experimental therapeutics 20110401

In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.

The Journal of pharmacology and experimental therapeutics 20110401

S-Petasin, the Main Sesquiterpene of Petasites formosanus, Inhibits Phosphodiesterase Activity and Suppresses Ovalbumin-Induced Airway Hyperresponsiveness.

Evidence-based complementary and alternative medicine : eCAM 20110101

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Respiratory research 20110101

Inhibition of granulocyte migration by tiotropium bromide.

Respiratory research 20110101

Cilomilast counteracts the effects of cigarette smoke in airway epithelial cells.

Cellular immunology 20110101

Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.

Evidence-based complementary and alternative medicine : eCAM 20110101

New therapeutic options in the management of COPD - focus on roflumilast.

International journal of chronic obstructive pulmonary disease 20110101

β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.

PloS one 20110101

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.

Respiratory research 20110101

Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.

Pulmonary medicine 20110101

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

Respiratory research 20110101

Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.

Journal of biomedical science 20110101

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20110101

Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.

Fundamental & clinical pharmacology 20100201

Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

BMC pulmonary medicine 20100101

Pharmacological studies of bronchial constriction inhibited by parasympatholytics and cilomilast using equine precision-cut lung slices.

Berliner und Munchener tierarztliche Wochenschrift 20100101

Influencing the decline of lung function in COPD: use of pharmacotherapy.

International journal of chronic obstructive pulmonary disease 20100101

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Drug design, development and therapy 20100101

Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.

Arzneimittel-Forschung 20100101

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

The Journal of pharmacology and experimental therapeutics 20090901

Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD.

Thorax 20090801

A phosphodiesterase inhibitor, cilomilast, enhances cAMP activity to restore conditioned odor preference memory after serotonergic depletion in the neonate rat.

Neurobiology of learning and memory 20090701

Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?

The European respiratory journal 20090501

Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia.

The European respiratory journal 20090401

Pharmacology of a novel, orally active PDE4 inhibitor.

Pharmacology 20090101

A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.

Respiratory research 20090101

Exacerbation rate, health status and mortality in COPD--a review of potential interventions.

International journal of chronic obstructive pulmonary disease 20090101

Targeted treatment in COPD: a multi-system approach for a multi-system disease.

International journal of chronic obstructive pulmonary disease 20090101

Chronic obstructive pulmonary disease: towards pharmacogenetics.

Genome medicine 20090101

ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

International journal of chronic obstructive pulmonary disease 20081201

PDE4 inhibitors: current status.

British journal of pharmacology 20081001

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

British journal of pharmacology 20081001

Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.

Journal of medicinal chemistry 20080925

Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.

Journal of dermatological science 20080901

Airways inflammation and treatment during acute exacerbations of COPD.

International journal of chronic obstructive pulmonary disease 20080601

Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(4-phenylethynyl-phenyl)-1H-benzimidazoles and N-substituted 2[4-(4,4-dimethyl-thiochroman-6-yl-ethynyl)-phenyl)-1H-benzimidazoles.

European journal of medicinal chemistry 20080501

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

Cellular signalling 20080501

Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

The Biochemical journal 20080415

Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.

COPD 20080201

Bronchiolar chemokine expression is different after single versus repeated cigarette smoke exposure.

Respiratory research 20080101

New drugs targeting Th2 lymphocytes in asthma.

Journal of occupational medicine and toxicology (London, England) 20080101

Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.

PloS one 20080101

The efficacy and safety of cilomilast in COPD. Forward.

Drugs 20080101

The efficacy and safety of cilomilast in COPD.

Drugs 20080101

[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].

Tuberkuloz ve toraks 20080101

Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes.

Drug design, development and therapy 20080101

Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease.

International journal of chronic obstructive pulmonary disease 20071201

Treating COPD with PDE 4 inhibitors.

International journal of chronic obstructive pulmonary disease 20071201

Future therapeutic treatment of COPD: struggle between oxidants and cytokines.

International journal of chronic obstructive pulmonary disease 20070901

Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).

The Journal of pharmacology and experimental therapeutics 20070801

L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

Biochemical pharmacology 20070615

Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.

American journal of physiology. Heart and circulatory physiology 20070601

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

International journal of chronic obstructive pulmonary disease 20070601

Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

Current opinion in investigational drugs (London, England : 2000) 20070501

Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.

Veterinary dermatology 20070401

Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.

Inflammation & allergy drug targets 20070301

SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

Journal of medicinal chemistry 20070125

Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs.

Pulmonary pharmacology & therapeutics 20070101

Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human.

Pulmonary pharmacology & therapeutics 20070101

Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.

Expert opinion on investigational drugs 20070101

Cyclic AMP signalling pathways in the regulation of uterine relaxation.

BMC pregnancy and childbirth 20070101

Maternal allergic contact dermatitis causes increased asthma risk in offspring.

Respiratory research 20070101

Bronchial epithelial spheroids: an alternative culture model to investigate epithelium inflammation-mediated COPD.

Respiratory research 20070101

Airways disease: phenotyping heterogeneity using measures of airway inflammation.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101

The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20061201

Evaluation of PDE4 inhibition for COPD.

International journal of chronic obstructive pulmonary disease 20061201

Pharmacological treatment of chronic obstructive pulmonary disease.

International journal of chronic obstructive pulmonary disease 20061201

Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.

The European respiratory journal 20061101

Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.

Life sciences 20061012

Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.

European journal of pharmacology 20061010

Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal.

Journal of pharmacokinetics and pharmacodynamics 20061001

Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.

The Annals of pharmacotherapy 20061001

Biological targets for therapeutic interventions in COPD: clinical potential.

International journal of chronic obstructive pulmonary disease 20060901

An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.

British journal of clinical pharmacology 20060801

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice.

The European respiratory journal 20060601

Preferential inhibition of human phosphodiesterase 4 by ibudilast.

Life sciences 20060501

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Current opinion in investigational drugs (London, England : 2000) 20060501

[Pharmacological treatment of COPD and future of anti-inflammatory therapy].

Medizinische Klinik (Munich, Germany : 1983) 20060415

Cilomilast.

Drugs of today (Barcelona, Spain : 1998) 20060401

Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.

Clinical therapeutics 20060401

Phosphodiesterase inhibitors in airways disease.

European journal of pharmacology 20060308

Eosinophilic airway inflammation in COPD.

International journal of chronic obstructive pulmonary disease 20060301

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

Pulmonary pharmacology & therapeutics 20060101

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Respiratory research 20060101

COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.

Chest 20060101

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

Chest 20060101

Clinical pharmacology of Cilomilast.

Clinical pharmacokinetics 20060101

The potential role of phosphodiesterase inhibitors in the management of asthma.

Treatments in respiratory medicine 20060101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060101

Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

Current medicinal chemistry 20060101

Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis.

The British journal of dermatology 20050701

Research on airway inflammation: present status in Mainland China.

Chinese medical journal 20050620

Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes.

Journal of immunology (Baltimore, Md. : 1950) 20050615

Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene.

Molecular pharmacology 20050601

PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.

Pharmacology & therapeutics 20050601

Cilomilast GlaxoSmithKline.

Current opinion in investigational drugs (London, England : 2000) 20050501

Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.

Expert review of clinical immunology 20050501

CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.

British journal of pharmacology 20050401

Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.

Current opinion in pulmonary medicine 20050301

Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.

Memorias do Instituto Oswaldo Cruz 20050301

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

Thorax 20050201

Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.

Pulmonary pharmacology & therapeutics 20050101

The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.

Pulmonary pharmacology & therapeutics 20050101

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Lancet (London, England) 20050101

The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.

Pulmonary pharmacology & therapeutics 20050101

Potentiation and prolongation of long-term odor memory in neonate rats using a phosphodiesterase inhibitor.

Neuroscience 20050101

Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.

Proceedings of the American Thoracic Society 20050101

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.

Core evidence 20050101

Structural basis for the activity of drugs that inhibit phosphodiesterases.

Structure (London, England : 1993) 20041201

Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.

Chinese medical journal 20041101

TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines.

The British journal of dermatology 20041001

Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.

British journal of pharmacology 20040901

Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers.

Journal of clinical pharmacology 20040901

Highly potent PDE4 inhibitors with therapeutic potential.

Bioorganic & medicinal chemistry 20040901

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

Trends in pharmacological sciences 20040801

Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.

Life sciences 20040702

Cytokines modulate cilomilast response in lung fibroblasts.

Clinical immunology (Orlando, Fla.) 20040601

PDE4 inhibitors in COPD--a more selective approach to treatment.

Respiratory medicine 20040601

Orally active PDE4 inhibitors with therapeutic potential.

Bioorganic & medicinal chemistry letters 20040308

Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.

Biology of reproduction 20040201

Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.

The Journal of pharmacology and experimental therapeutics 20040201

Highly potent PDE4 inhibitors with therapeutic potential.

Bioorganic & medicinal chemistry letters 20040105

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040101

[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20040101

Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin.

European journal of pharmacology 20031128

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

American journal of respiratory and critical care medicine 20031015

Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?

American journal of respiratory and critical care medicine 20031015

In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.

The Journal of pharmacology and experimental therapeutics 20031001

AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.

The Journal of pharmacy and pharmacology 20030801

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Thorax 20030701

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.

Journal of medicinal chemistry 20030508

Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.

The Journal of pharmacology and experimental therapeutics 20030501

[Physiopathology of COPD: choosing the right therapeutic targets].

Revue de pneumologie clinique 20030401

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

Pulmonary pharmacology & therapeutics 20030101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030101

Therapy for chronic obstructive pulmonary disease in the 21st century.

Drugs 20030101

Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Drugs 20030101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20021101

Crystal structure of phosphodiesterase 4D and inhibitor complex(1).

FEBS letters 20021023

Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.

American journal of respiratory cell and molecular biology 20021001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20021001

Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model.

Transplantation 20020815

Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.

The Journal of pharmacology and experimental therapeutics 20020701

Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis.

European journal of pharmacology 20020620

Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.

Journal of medicinal chemistry 20020606

Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.

Journal of medicinal chemistry 20020606

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

Bioorganic & medicinal chemistry letters 20020603

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.

American journal of respiratory cell and molecular biology 20020601

Phosphodiesterase 4 inhibitors for the treatment of COPD.

Chest 20020501

Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.

The Journal of pharmacology and experimental therapeutics 20020401

Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.

Bioorganic & medicinal chemistry letters 20020225

Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20020201

Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.

Bioorganic & medicinal chemistry letters 20020121

Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux.

Biochemical and biophysical research communications 20020118

Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.

Bioorganic & medicinal chemistry letters 20020107

Update on the therapeutic potential of PDE4 inhibitors.

Expert opinion on investigational drugs 20020101

Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.

Pulmonary pharmacology & therapeutics 20020101

Warfarin pharmacodynamics unaffected by cilomilast.

The Annals of pharmacotherapy 20011201

Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.

British journal of pharmacology 20011101

Cilomilast: a breath of relief?

Trends in molecular medicine 20011001

An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers.

Journal of clinical pharmacology 20010901

Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.

Journal of medicinal chemistry 20010802

Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.

Journal of medicinal chemistry 20010802

The next generation of PDE4 inhibitors.

Current opinion in chemical biology 20010801

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.

Lancet (London, England) 20010728

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.

Expert opinion on investigational drugs 20010701

Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.

Pharmacotherapy 20010601

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.

Clinical therapeutics 20010601

Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.

European journal of pharmacology 20010406

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

The Journal of pharmacology and experimental therapeutics 20010401

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

The Journal of pharmacology and experimental therapeutics 20010401

Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.

Bioorganic & medicinal chemistry letters 20010312

Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.

Bioorganic & medicinal chemistry letters 20010108

Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.

Pulmonary pharmacology & therapeutics 20010101

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Pulmonary pharmacology & therapeutics 19990101

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

The Journal of pharmacology and experimental therapeutics 19981101

SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

The Journal of pharmacology and experimental therapeutics 19980101